Inclusion Criteria:~* 60 years of age or older~* Diagnosis of probable mild-to-moderate Alzheimer's Disease~*
On a stable dose of an acetylcholinesterase inhibitor (including, but not limited to: donepezil, galantamine,
rivastigmine, and tacrine) for at least 120 days prior to baseline and will likely remain on the drug
throughout the trial; all participants must be on acetylcholinesterase inhibitors~* No other significant or
interfering medical conditions~
